Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jayme Trahan

Neurological Surgery Lafayette, LA Medical Doctor

NPI 1700072238 CMS profile 1094975

1000 W Pinhook Rd Ste 305, Ste 305, Lafayette, LA 70503

Open in the dashboard

General payments

$67,531

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$600,000

6 holdings reported · through program year 2025

Through program year 2025, Jayme Trahan of Lafayette, LA is reported in the CMS Open Payments database as having received $67,531 across 103 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $600,000 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,784 3
2024 General $145 2
2023 General $4,867 8
2022 General $12,355 17
2021 General $13,249 14
2020 General $17,937 26
2019 General $15,193 33
2025 Ownership $100,000 1
2024 Ownership $100,000 1
2023 Ownership $100,000 1
2022 Ownership $100,000 1
2021 Ownership $100,000 1
2020 Ownership $100,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jayme Trahan
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Jayme Trahan were reported at $3,784. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Jayme Trahan Neurological Surgery median Middle half National median
2019 $15,193 $582 $138–$3,006 $163
2020 $17,937 $294 $76–$2,174 $114
2021 $13,249 $387 $105–$2,432 $132
2022 $12,355 $542 $139–$2,989 $149
2023 $4,867 $534 $145–$2,697 $160
2024 $145 $574 $155–$3,046 $164
2025 $3,784 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. The Institute of Musculoskeletal Science and Education $63,610 27 payments
  2. Boston Scientific Corporation $1,046 27 payments
  3. SI-BONE, Inc. $881 10 payments
  4. Stryker Corporation $550 4 payments
  5. Philadelphia Medical Management Company LLC $307 2 payments
  6. Providence Medical Technology, Inc. $223 3 payments
  7. DePuy Synthes Sales Inc. $213 9 payments
  8. Orthofix Medical, Inc. $178 2 payments
  9. Relievant Medsystems, Inc. $118 7 payments
  10. Abbott Laboratories $93 3 payments
  11. Other $313 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $59,933 20 payments
  2. Food and Beverage $3,074 73 payments
  3. Travel and Lodging $2,088 5 payments
  4. Consulting Fee $1,600 2 payments
  5. Gift $530 1 payment
  6. Current or prospective ownership or investment interest $307 2 payments
Products named General payments · program years 2019–2025
  1. Enza 2.0 $26,054 8 payments
  2. Spira $16,405 6 payments
  3. Enza $3,636 2 payments
  4. IVS - VERTEBRAL AUGMENTATION PRODUCTS $396 1 payment
  5. IFUSE IMPLANT $282 6 payments
  6. General - Pain Management $223 2 payments
  7. Intracept $148 1 payment
  8. General Therapies $139 2 payments
  9. FIBERGRAFT $125 5 payments
  10. SPECTRA WAVEWRITER $121 3 payments
  11. Other $1,601 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Neurosurgery: 83

Drug cost

$22

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 14 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$144,429

Of which drugs: $97

Medicare patients

338

Average age 73

Services billed

1,775

159 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 40%
Diabetes 39%
Depression 30%
Chronic kidney disease 21%
Atrial fibrillation 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 680 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record